Stock NOVN NOVARTIS AG
Add to a list
To use this feature you must be a member
Log inSign up

News Novartis AG

Equities

NOVN

CH0012005267

Delayed Swiss Exchange
Other stock markets
 10:31:08 2024-04-19 am EDT 		5-day change 1st Jan Change
85.04 CHF +0.62% Intraday chart for Novartis AG -1.23% +0.20%
12:33am US FDA mandates label updates on CAR-T cancer therapies RE
Apr. 18 NOVARTIS AG : UBS reiterates its Buy rating ZD

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
US FDA mandates label updates on CAR-T cancer therapies
RE
NOVARTIS AG : UBS reiterates its Buy rating
ZD
TotalEnergies: shareholders want to separate powers
CF
NOVARTIS AG : Deutsche Bank maintains a Buy rating
ZD
Novartis' Multiple Sclerosis Drug Shows Sustained Efficacy for Up to Six Years
MT
Novartis: positive efficacy data in MS
CF
Novartis Kesimpta(R) six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
DJ
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
GL
Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB?s Bimzelx Poised to Further Disrupt the Market
CI
Novartis reports positive interim results for Fabhalta
CF
Novartis' Investigational Kidney Disease Drug Shows Reduced Disease Marker in Late-stage Trial
MT
Health Care Ticks Down Amid Rotation From Rate-Sensitive Sectors -- Health Care Roundup
DJ
Novartis' Fabhalta Found to Lower Disease Marker in Kidney Disease Patients
MT
Novartis Gets Priority Review for Kidney Disease Treatment
DJ
New Novartis Fabhalta(R) (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
DJ
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
GL
Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta
CI
Arvinas enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer
AQ
MorphoSys Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
AQ
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NOVN Stock
  4. News Novartis AG